Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSC-DC vaccine
- Development stage
- Phase 2
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous (by Analogy To Other Dendritic Cell Vaccines, Not Explicitly Stated), Subcutaneous (by Analogy To Other Dendritic Cell Vaccines, Not Explicitly Stated)
01
Overview
The CSC-DC vaccine is an **experimental cancer vaccine** designed to stimulate the immune system to target cancer stem cells (CSCs) by pulsing autologous dendritic cells (DCs) with lysates of ALDHhigh-enriched cancer stem cells. This approach aims to induce CSC-specific cytotoxic T lymphocyte (CTL) and antibody responses, reduce the population of CSCs within tumors, and block metastasis. Mechanistic studies show the vaccine triggers host immunity specifically against CSCs and may reduce metastatic dissemination by downregulating chemokine receptors (CCR7, CCR10) and their ligands in target organs. Its efficacy has been demonstrated in preclinical syngeneic murine tumor models and is under exploration in combination regimens with immune checkpoint inhibitors (such as anti–PD-L1 antibodies) for enhanced tumor control[1][2][3][6][10].
- Other names
- cancer stem cell-dendritic cell vaccineCSC-dendritic cell vaccine
02
Targets
CCR10 (C-C chemokine receptor type 10)ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)
Beyond the preview
Go deeper on CSC-DC vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSC-DC vaccine.